Pegfilgrastim
- Generic Name
- Pegfilgrastim
- Brand Names
- Fulphila, Fylnetra, Neulasta, Udenyca, Ziextenzo, Cegfila (previously Pegfilgrastim Mundipharma), Nyvepria, Pelgraz, Grasustek, Pelmeg, Stimufend
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 208265-92-3
- Unique Ingredient Identifier
- 3A58010674
- Background
Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti-cancer treatment. Although the risk of de...
- Indication
Pegfilgrastim is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
...
- Associated Conditions
- Chemotherapy Induced Neutropenia, Hematopoietic Subsyndrome of Acute Radiation Syndrome, Infection
- Associated Therapies
- -
Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer
- Conditions
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2023-08-02
- Lead Sponsor
- Harold J. Burstein, MD, PhD
- Target Recruit Count
- 135
- Registration Number
- NCT00146562
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
A Study of Cyclophosphamide/Methotrexate/5-Fluorouracil (CMF) With Pegfilgrastim in Subjects With Breast Cancer
- Conditions
- First Posted Date
- 2005-07-27
- Last Posted Date
- 2010-02-26
- Lead Sponsor
- Amgen
- Registration Number
- NCT00124111
Treatment for Subjects With Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2005-07-11
- Last Posted Date
- 2009-07-20
- Lead Sponsor
- Amgen
- Registration Number
- NCT00117897
Treatment for Elderly Patients With High Risk Breast Cancer
- Conditions
- First Posted Date
- 2005-07-11
- Last Posted Date
- 2008-05-16
- Lead Sponsor
- Amgen
- Registration Number
- NCT00117910
Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
- First Posted Date
- 2005-07-11
- Last Posted Date
- 2021-11-17
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 524
- Registration Number
- NCT00118209
- Locations
- 🇺🇸
Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States
🇺🇸Charles R. Wood Cancer Center at Glens Falls Hospital, Glens Falls, New York, United States
🇺🇸Madigan Army Medical Center - Tacoma, Tacoma, Washington, United States
A Study of Peripheral Blood Progenitor Cell (PBPC) Mobilisation by Chemotherapy With Pegfilgrastim or Filgrastim in Subjects With Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2005-07-07
- Last Posted Date
- 2008-05-16
- Lead Sponsor
- Amgen
- Registration Number
- NCT00117455
A Study of Carboplatin/Paclitaxel With Pegfilgrastim Supported by Haematopoietic Progenitor Cell Re-Infusion in Whole Blood
- Conditions
- Interventions
- First Posted Date
- 2005-07-07
- Last Posted Date
- 2013-05-13
- Lead Sponsor
- Amgen
- Target Recruit Count
- 61
- Registration Number
- NCT00117442
Same Day Dosing of Pegfilgrastim in Breast Cancer Patients Undergoing Chemotherapy (TAC)
- Conditions
- First Posted Date
- 2005-06-23
- Last Posted Date
- 2008-08-01
- Lead Sponsor
- Amgen
- Registration Number
- NCT00115414
Pegfilgrastim Administered on the Same Day as Chemotherapy in Non-Hodgkin's Lymphoma
- First Posted Date
- 2005-06-22
- Last Posted Date
- 2013-08-29
- Lead Sponsor
- Amgen
- Target Recruit Count
- 77
- Registration Number
- NCT00115193
Trial Comparing Pegfilgrastim With Filgrastim as an Adjunct to Chemotherapy for Acute Myeloid Leukaemia (AML)
- First Posted Date
- 2005-06-20
- Last Posted Date
- 2008-10-31
- Lead Sponsor
- Amgen
- Target Recruit Count
- 84
- Registration Number
- NCT00114764
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.